Newsbenzinga
Over 88% Of Wegovy Trial Participants Achieve Normal Liver Fat Levels, Novo Reports
· Published
Article summary
Novo Nordisk's Wegovy significantly reduced liver fat in adults with obesity in a recent post hoc analysis, potentially lowering MASH risk.
An excerpt from the original article.
Comments —
Loading comments…